NCT07415135

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

Phase Ⅱ Clinical Study on the Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Zhu Yinjie · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, single-arm, open-label exploratory study to evaluate the safety and efficacy of fluorescent imaging combined with a robotic surgical control system for robot-assisted radical prostatectomy.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery	0.02 mg/kg
DRUG	0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery	0.04 mg/kg
DRUG	0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery	0.06 mg/kg

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2026-02-17
• Last updated: 2026-02-17